Azenta, Inc. (AZTA)

Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) and its peers.

CVR Medical (OTCMKTS:CRRVF – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, ...

Yet InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value estimate, trading at a high Price/Book multiple of 30.55. While the company wasn’t profitable over the last twelve months, analysts predict profitability this year with forecasted earnings of $0.28 ...

5 medical stocks growing earnings by triple digits · Azenta (NASDAQ:AZTA) reported fiscal second-quarter 2026 results that management said fell short of expectations, citing execution shortfalls and a cautious demand environment—particularly in North America—along with ongoing weakness ...

Azenta (AZTA) has put a tough quarter on the table, with Q2 2026 revenue of US$144.8 million and a basic EPS loss of US$3.41, alongside net income from continuing operations showing a loss of US$157.0 million. The company has seen quarterly revenue move from US$143.4 million in Q2 2025 to US$158.0 .…